AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 38315832
Drug: 3L chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3L chemotherapy with SCT after salvage chemotherapy (n=10)
Trial: 38315832
Drug: 3L chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3L chemotherapy without SCT after salvage chemotherapy (n=50)
Trial: 38315832
Drug: 3L cellular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3L cellular immunotherapy after 2L axi-cel (n=8)
Trial: 38315872
Drug: Single IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single IV dose of 1080 mg
Trial: 38315872
Drug: Subcutaneous (SC)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) dosing of 1080 mg on 3 consecutive days
Trial: 38315872
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment with pegcetacoplan (IV or SC)
Trial: 38315944
Drug: Trabectedin 1.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trabectedin 1.3 mg/m²
Trial: 38315945
Drug: Cinpanemab (human-derived
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinpanemab (human-derived monoclonal antibody) administered intravenously every 4 weeks for 52 weeks
Trial: 38316055
Drug: Patient-specific treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-specific treatment planning using measured, homogeneous optical properties
Trial: 38316133
Drug: Oral decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral decitabine 35 mg plus cedazuridine 100 mg on days 1-5 and venetoclax (400 mg) for 14 days
Trial: 38316236
Drug: Intraoperative dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intraoperative dexamethasone followed by a 6-day oral methylprednisolone taper course
Trial: 38316588
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral dose of three strains of probiotics
Trial: 38316601
Drug: Lean protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lean protein sources (e.g., chicken) replacing legumes in entrées.
Trial: 38317178
Drug: 5% albumin
RxNorm normalized name: Flexbumin 5% Albumin (Human) Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% albumin (12 mL/kg)
Trial: 38317178
Drug: 20% albumin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% albumin (3 mL/kg)
Trial: 38317420
Drug: Subcutaneous blinatumomab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous blinatumomab
Trial: 38318125
Drug: S48168 (ARM210)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S48168 (ARM210) 120 mg daily for 29 days
Trial: 38318125
Drug: S48168 (ARM210)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S48168 (ARM210) 200 mg daily for 29 days
Trial: 38318236
Drug: Efgartigimod (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efgartigimod (10 mg/kg infusion per week for 4 weeks)
Trial: 38318270
Drug: Heparin (3000-7500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (3000-7500 U for vascular surgery, 27,500-40,000 U for cardiac surgery)
Trial: 38318270
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin (5000 U subcutaneously)
Trial: 38318484
Drug: 0.01% menthol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.01% menthol solution
Trial: 38318484
Drug: Placebo noncaloric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo noncaloric solution
Trial: 38318773
Drug: Primary care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary care allied health treatment
Trial: 38318773
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment plan including physical exercise
Trial: 38319178
Drug: Molnupiravir 200
RxNorm normalized name: molnupiravir 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Molnupiravir 200 mg, 400 mg, or 800 mg, twice daily for 5 days
Trial: 38319178
Drug: Molnupiravir (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Molnupiravir (all doses combined)
Trial: 38319179
Drug: Molnupiravir (combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Molnupiravir (combined group of 200, 400, or 800 mg)
Trial: 38319181
Drug: Exercise therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise therapy and education (12-week supervised)
Trial: 38319181
Drug: Exercise therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise therapy and education
Trial: 38319229
Drug: Heart failure
RxNorm normalized name: INVESTIGATIONAL CONGESTIVE HEART FAILURE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heart failure treatment
Trial: 38319239
Drug: Low-dose subcutaneous
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose subcutaneous aldesleukin (recombinant IL-2), 0.3 to 3.0 × 106 IU daily for 5 consecutive days (part A)
Trial: 38319239
Drug: Low-dose subcutaneous
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose subcutaneous aldesleukin (recombinant IL-2), 1.5 and 2.5 × 106 IU daily for 5 consecutive days (part B)
Trial: 38319241
Drug: Zilovertamab vedotin
RxNorm normalized name: Zilovertamab vedotin
DrugBank: Zilovertamab vedotin (DB18457)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zilovertamab vedotin (ZV) at doses of 0.5, 1.0, 1.5, 2.25, and 2.5 mg/kg every 3 weeks until cancer progression or unacceptable toxicity.
Trial: 38319253
Drug: High-dose adeno-associated
RxNorm normalized name: ADENO-ASSOCIATED VIRUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose adeno-associated viral vector serotype 8 expressing ARSB
Trial: 38319253
Drug: Low and
RxNorm normalized name: ZINC OXIDE 88 mg in 1 mL TOPICAL LOTION [Ciele Glow and Protect]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low and intermediate dose cohorts of adeno-associated viral vector serotype 8 expressing ARSB
Trial: 38319689
Drug: AMH cutoff
RxNorm normalized name: Sodium Fluoride 0.007 mg in 35 mL ORAL SPRAY [AMHEALER]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMH cutoff of 3.2 ng/mL for the Elecsys AMH Plus or Elecsys AMH assays (Roche)
Trial: 38319800
Drug: Abiraterone (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abiraterone (1000 mg once daily) plus olaparib (300 mg twice daily)
Trial: 38319800
Drug: Abiraterone (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abiraterone (1000 mg once daily) plus placebo
Trial: 38319804
Drug: Infliximab discontinuation
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab discontinuation (placebo)
Trial: 38319812
Drug: Sabizabulin (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sabizabulin (9 mg orally daily for up to 21 days)
Trial: 38319837
Drug: Decitabine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decitabine (20 mg/m2 daily on days 1 to 3 every 28-day cycle)
Trial: 38319837
Drug: Azacitidine (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azacitidine (75 mg/m2 daily on days 1 to 3 every 28-day cycle)
Trial: 38319837
Drug: Decitabine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decitabine (20 mg/m2 daily)
Trial: 38319837
Drug: Azacitidine (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azacitidine (75 mg/m2 daily)
Trial: 38319852
Drug: Pembrolizumab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab (200 mg intravenously every 3 weeks for a total of 18 doses)
Trial: 38319892
Drug: STRIDE (tremelimumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STRIDE (tremelimumab 300 mg, one dose plus durvalumab 1500 mg every 4 weeks)
Trial: 38319892
Drug: Durvalumab (1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab (1500 mg every 4 weeks)
Trial: 38319910
Drug: Nutritional status
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional status assessment using bioelectrical impedance analysis (BIA) throughout multimodal treatment.
Trial: 38320023
Drug: Nivolumab +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab + Relatlimab (480 mg + 160 mg fixed-dose combination)
Trial: 38320023
Drug: Nivolumab (480
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (480 mg alone)
Trial: 38320033
Drug: Low-dose low-molecular-weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose low-molecular-weight heparin thromboprophylaxis
Trial: 38320033
Drug: Intermediate-dose low-molecular-weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermediate-dose low-molecular-weight heparin thromboprophylaxis
Trial: 38320033
Drug: Low-dose plus
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose plus aspirin
Trial: 38320033
Drug: Therapeutic-dose anticoagulation
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic-dose anticoagulation
Trial: 38320088
Drug: Females, BMI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Females, BMI ≥23 kg/m2, No.12 lymph node dissection, adjuvant chemotherapy
Trial: 38320097
Drug: Increased water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased water intake (exact dosage and duration not specified)
Trial: 38320126
Drug: Ropeginterferon alfa-2b
RxNorm normalized name: Ropeginterferon alfa-2b
DrugBank: Ropeginterferon alfa-2b (DB15119)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ropeginterferon alfa-2b (ropeg; 100 μg every 2 weeks)
Trial: 38320126
Drug: Phlebotomy only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phlebotomy only (standard therapy)
Trial: 38320129
Drug: Avapritinib 25
RxNorm normalized name: avapritinib 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avapritinib 25 mg once daily
Trial: 38320142
Drug: Enoxaparin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (40 mg/day for 6 to 14 days)
Trial: 38320144
Drug: Nalbuphine extended-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalbuphine extended-release tablets (NAL ER) started at a dose of 27 mg once daily, titrated up to 162 mg twice daily at day 16.
Trial: 38320144
Drug: Nalbuphine extended-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalbuphine extended-release tablets (NAL ER)
Trial: 38320155
Drug: 4-month regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-month regimen of rifampicin at 1800 mg/d (SR2)
Trial: 38320155
Drug: 4-month regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-month regimen of rifampicin at 1200 mg/d (SR1)
Trial: 38320181
Drug: Tezepelumab (210
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tezepelumab (210 mg every 4 weeks subcutaneously for at least 28 weeks)
Trial: 38320179
Drug: Vemurafenib 960
RxNorm normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vemurafenib 960 mg twice daily for four cycles plus obinutuzumab administered in cycles 2 to 4
Trial: 38320240
Drug: Interfascial injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interfascial injection of 10 mL of 10% dextrose water
Trial: 38320240
Drug: Sham injection
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham injection of 0.5 mL of 10% dextrose water
Trial: 38320431
Drug: Peposertib 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peposertib 200 mg b.i.d. plus avelumab
Trial: 38320431
Drug: Peposertib 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peposertib 250 mg q.d. plus avelumab and radiotherapy
Trial: 38320431
Drug: Recommended phase
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recommended phase II dose (RP2D) and maximum tolerated dose (MTD)
Trial: 38320431
Drug: Pharmacokinetics of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacokinetics of peposertib
Trial: 38320464
Drug: Uncontrolled glycemia
RxNorm normalized name: Glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uncontrolled glycemia (glucose levels ≥175 mg/dL)
Trial: 38320464
Drug: Controlled glycemia
RxNorm normalized name: Glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled glycemia (glucose levels <175 mg/dL)
Trial: 38320488
Drug: Two-dose 9vHPV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-dose 9vHPV vaccine (0 and 6 months)
Trial: 38320488
Drug: Three-dose 9vHPV
RxNorm normalized name: THREE-LOBE SAGE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-dose 9vHPV vaccine (0, 2, and 6 months)
Trial: 38320488
Drug: Two-dose 9vHPV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-dose 9vHPV vaccine
Trial: 38320488
Drug: Three-dose 9vHPV
RxNorm normalized name: THREE-LOBE SAGE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-dose 9vHPV vaccine
Trial: 38320498
Drug: ARO-APOC3 10
RxNorm normalized name: ARO-APOC3
DrugBank: ARO-APOC3 (DB17625)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARO-APOC3 10 mg
Trial: 38320498
Drug: ARO-APOC3 25
RxNorm normalized name: ARO-APOC3
DrugBank: ARO-APOC3 (DB17625)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARO-APOC3 25 mg
Trial: 38320498
Drug: ARO-APOC3 50
RxNorm normalized name: ARO-APOC3
DrugBank: ARO-APOC3 (DB17625)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARO-APOC3 50 mg
Trial: 38320498
Drug: ARO-APOC3 100
RxNorm normalized name: ARO-APOC3
DrugBank: ARO-APOC3 (DB17625)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARO-APOC3 100 mg
Trial: 38320500
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of dapagliflozin
Trial: 38320500
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg of saxagliptin
Trial: 38320501
Drug: Combination (enzalutamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination (enzalutamide plus leuprolide)
Trial: 38320501
Drug: Monotherapy (enzalutamide)
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy (enzalutamide)
Trial: 38320513
Drug: ODM-208 5
RxNorm normalized name: ODM-203
DrugBank: ODM-203 (DB16843)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ODM-208 5 mg twice daily with glucocorticoid/mineralocorticoid replacement
Trial: 38320513
Drug: ODM-208 5
RxNorm normalized name: ODM-203
DrugBank: ODM-203 (DB16843)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ODM-208 5 mg twice daily
Trial: 38320524
Drug: Difelikefalin 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Difelikefalin 0.5 μg/kg intravenously three times per week for 6 weeks
Trial: 38320840
Drug: Education about
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Education about genomic medicine provided to neonatal providers
Trial: 38321023
Drug: agenT-797 (donor-unrestricted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: agenT-797 (donor-unrestricted allogeneic ex vivo expanded iNKT cell therapy)
Trial: 38321218
Drug: OMO-103 (6.48
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OMO-103 (6.48 mg/kg, DL5)
Trial: 38321220
Drug: UBX1325 (foselutoclax),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UBX1325 (foselutoclax), a senolytic small-molecule inhibitor of BCL-xL
Trial: 38321617
Drug: Behaviorally-based treatments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behaviorally-based treatments
Trial: 38322553
Drug: AllerPops prebiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AllerPops prebiotic supplements
Trial: 38322862
Drug: Esketamine infusion
RxNorm normalized name: esketamine
DrugBank: Esketamine (DB11823)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Esketamine infusion (0.75 mcg/ml) combined with sufentanil (1.5 mcg/ml) for 24 hours
Trial: 38322862
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (sufentanil 1.5 mcg/ml alone)
Trial: 38322981
Drug: Cannabidiol (CBD)
RxNorm normalized name: cannabidiol (CBD)
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cannabidiol (CBD) 25 mg 3 times/day if <80 kg and 50 mg 3 times/day if >80 kg for 14 days
Trial: 38323173
Drug: Intravenous fosaprepitant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous fosaprepitant (arm A)
Trial: 38323173
Drug: Oral aprepitant
RxNorm normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral aprepitant (arm B)
Trial: 38323513
Drug: Personalized amlodipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized amlodipine dose titration (novel doses: 1, 2, 3, 4, 6, 7, 8, 9 mg; standard doses: 5 and 10 mg) over 14 weeks.
Trial: 38323949
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy-based Creating Opportunities for Personal Empowerment program
Trial: 38324085
Drug: Navarixin 30
RxNorm normalized name: Navarixin
DrugBank: Navarixin (DB11711)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Navarixin 30 mg plus pembrolizumab
Trial: 38324085
Drug: Navarixin 100
RxNorm normalized name: Navarixin
DrugBank: Navarixin (DB11711)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Navarixin 100 mg plus pembrolizumab
Trial: 38324085
Drug: Navarixin 30
RxNorm normalized name: Navarixin
DrugBank: Navarixin (DB11711)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Navarixin 30 mg
Trial: 38324085
Drug: Navarixin 100
RxNorm normalized name: Navarixin
DrugBank: Navarixin (DB11711)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Navarixin 100 mg
Trial: 38324280
Drug: β-blocker withdrawal
RxNorm normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: β-blocker withdrawal
Trial: 38324367
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy-based treatment app (Spark)
Trial: 38324415
Drug: Apixaban, 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apixaban, 5 mg or 2.5 mg, twice daily (n=507)
Trial: 38324415
Drug: Aspirin, 81
RxNorm normalized name: Aspirin, 81 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin, 81 mg, once daily (n=508)
Trial: 38324484
Drug: JNJ-77242113 25
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-77242113 25 mg once daily
Trial: 38324484
Drug: JNJ-77242113 25
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-77242113 25 mg twice daily
Trial: 38324484
Drug: JNJ-77242113 50
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-77242113 50 mg once daily
Trial: 38324484
Drug: JNJ-77242113 100
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-77242113 100 mg once daily
Trial: 38324484
Drug: JNJ-77242113 100
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-77242113 100 mg twice daily
Trial: 38324741
Drug: Crenolanib plus
RxNorm normalized name: Crenolanib
DrugBank: Crenolanib (DB11832)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crenolanib plus intensive chemotherapy
Trial: 38325290
Drug: Penicillin Skin
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Penicillin Skin Testing (PST) followed by amoxicillin 250 mg challenge
Trial: 38325290
Drug: Graded Oral
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Graded Oral Challenge (GOC) with amoxicillin 25 mg followed by 250 mg
Trial: 38325328
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg intravenously every 3 weeks in conjunction with glass yttrium-90 (Y90) radioembolization TheraSphere
Trial: 38325765
Drug: Protein intake
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein intake of 1.08 g⋅kg
Trial: 38325988
Drug: Roux-en-Y gastric
RxNorm normalized name: gastric mucins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roux-en-Y gastric bypass (RYGB) combined with medical therapy (MT)
Trial: 38326352
Drug: Escitalopram (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram (20 mg daily)
Trial: 38326734
Drug: High-Intensity Resistance
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Intensity Resistance Training (HIRT) for 16 months, twice weekly
Trial: 38326920
Drug: Human serum
RxNorm normalized name: Human serum albumin
DrugBank: Albumin human (DB00062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human serum albumin 20% 100 mL over 15 min
Trial: 38326920
Drug: Saline 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline 500 mL
Trial: 38327730
Drug: Medication-free treatment
RxNorm normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication-free treatment